James S. Scibetta

This profile gathers the share dealings of James S. Scibetta across 4 companies, led by Pacira BioSciences, Inc., Matinas BioPharma Holdings, Inc. and Aquestive Therapeutics, Inc. In total, 60 filings cover trades dated from 15 February 2011 to 19 June 2021.

In open-market terms, that means 6 purchases worth €382k on one side and 24 sales worth €9.1M on the other. The net balance comes to €8.7M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 11 share grants and 15 option exercises.

In size, the median ticket on the buying side is €31k. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 6 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +61.0%. These figures describe past trades and do not predict future prices.

On 24 June 2021 came the latest disclosure, a transaction in Matinas BioPharma Holdings, Inc. The latest purchase dates back some time: it was published 2,635 days ago, on 22 August 2019. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.